Deep Research Summary: Lowe Syndrome

Research Method

Manual disease curation performed on 2026-04-12 to 2026-04-13 using PubMed, MONDO/OAK term lookup, and local dismech validation workflows.

Primary goals: - frame the disease correctly against the broader OCRL-related spectrum - keep the mechanistic graph atomic rather than bundled - prefer PMID-backed primary studies for the YAML evidence items - use review papers mainly for prevalence, progression, and standard-of-care summaries

Disease Framing

This curation is intentionally for classic Lowe syndrome / oculocerebrorenal syndrome (MONDO:0010645), not for a lumped "OCRL-related disorder" entry.

Reasons for splitting from Dent disease-2 at the disease level: - PMID:25480730 describes Lowe syndrome as a rare X-linked multisystem disorder "almost always characterized by the triad of congenital cataract, cognitive and behavioral impairment and a proximal tubulopathy." - PMID:18480301 shows that the renal phenotype overlaps strongly with Dent disease, especially low-molecular-weight proteinuria and hypercalciuria. - PMID:34586410 provides a mechanistic explanation for part of the allelic split: truncating variants in exons 1-7 can preserve an OCRL isoform and are more associated with Dent disease-2, whereas truncating variants in exons 8-24 are associated with classic Lowe syndrome.

Working curation choice: - keep Lowe syndrome as the severe syndromic OCRL disease - explicitly note the OCRL allelic continuum in genetic.notes and notes - prioritize mechanistic edges that are shared across the OCRL spectrum only when they plausibly explain the syndromic Lowe phenotype

Main Mechanistic Story

The most coherent disease-level mechanism is:

1. OCRL loss reduces phosphatidylinositol 4,5-bisphosphate 5-phosphatase activity.
2. PI(4,5)P2 accumulates abnormally on early endosomes.
3. Excess endosomal PI(4,5)P2 drives abnormal F-actin assembly.
4. Endosomal and clathrin-mediated receptor recycling become defective.
5. In proximal tubule cells this disrupts megalin-dependent reabsorption and produces the dominant renal phenotype.
6. In parallel, OCRL loss alters ciliary phosphoinositides and cilium maintenance, plausibly contributing to eye disease, especially glaucoma.

Key papers anchoring those nodes: - PMID:7761412 foundational biochemical identification of OCRL as a phosphatidylinositol 4,5-bisphosphate 5-phosphatase. - PMID:21971085 strongest single paper for the endosomal PI(4,5)P2 -> endosomal actin -> megalin recycling story. - PMID:15917292 and PMID:25107275 support clathrin-dependent trafficking and endocytosis defects as distinct atomic steps. - PMID:25838181 gives in vivo renal support in zebrafish and identifies PIP5K suppression as a mechanistically interesting therapeutic direction. - PMID:22543976 and PMID:28871046 support the ciliary branch of disease. - PMID:25143588 supports the specific glaucoma-relevant hypothesis that OCRL is required for pressure-responsive ciliary signaling in trabecular meshwork cells.

Why Some Mechanisms Were Excluded

Several OCRL-adjacent processes were considered but not promoted into the YAML graph because the disease-level support was weaker or too indirect: - lysosome positioning / mTORC1 nutrient sensing - generalized Golgi dysfunction without a clean disease link - broad "ciliopathy" labeling of Lowe syndrome as a parent category - bundled "endolysosomal dysfunction" nodes that mix phosphoinositides, actin, trafficking, and organ phenotypes in one statement

The curation instead keeps those processes decomposed into smaller nodes that are better supported by the abstracts and more reusable across related disorders.

Clinical Phenotype Prioritization

Phenotypes retained in the YAML were limited to well-supported, central disease features: - bilateral congenital cataract - glaucoma - generalized hypotonia - global developmental delay - renal tubular dysfunction - low-molecular-weight proteinuria - hypercalciuria - chronic kidney disease

Why these were prioritized: - PMID:32340490 provides quantitative ophthalmic data in 137 affected individuals, including 100% bilateral congenital cataract and 54.7% glaucoma. - PMID:18480301 gives the clearest quantitative renal phenotype data for low-molecular-weight proteinuria and hypercalciuria. - PMID:27708066 establishes CKD burden and faster progression in Lowe syndrome versus Dent disease-2. - PMID:16722554 is still useful for the classic onset sequence and treatment overview despite being a review.

Phenotypes reviewed but not promoted into the YAML: - short stature - undescended testes - dental problems - fractures / hypophosphatemia - thrombocytopenia - hyperacusis / hyperosmia

These are real and supported in the literature, especially PMID:35803701 and PMID:25480730, but they were treated as secondary modifiers rather than core disease-defining phenotypes for this first-pass disease entry.

Treatment Curation Decisions

The entry keeps treatment claims conservative and symptom-focused: - cataract extraction - glaucoma surgery - renal tubular loss replacement / supportive care

Reasons: - PMID:16722554 gives the most compact standard-of-care summary. - PMID:32340490 provides practical retrospective evidence for glaucoma procedures, with aqueous tube shunts noted as the best-performing approach in that dataset. - PMID:35847784 adds direct infant case evidence for combined cataract and minimally invasive glaucoma surgery. - PMID:18480301 supports bicarbonate and phosphate replacement as real-world supportive treatment for tubular losses.

What was not added: - experimental PIP5K-targeted therapy - broad developmental/behavioral therapies as separate treatment nodes

Those are worth tracking, but the current evidence base is thinner or more indirect than the surgical and renal-supportive measures above.

Evidence Source Choices

Evidence source assignments in the YAML were chosen by study design, not by how the curation was performed: - HUMAN_CLINICAL: cohort studies, retrospective surveys, case reports with direct patient data - IN_VITRO: patient fibroblasts, cultured cells, biochemical assays - MODEL_ORGANISM: zebrafish renal and ciliary studies - OTHER: review articles used only for prevalence / progression / management summaries when cleaner primary abstract text was not available

Notable examples: - PMID:16722554 is tagged OTHER because it is a review article. - PMID:21971085 is tagged IN_VITRO because the supporting claims come from cell-based mechanistic work. - PMID:25838181 is tagged MODEL_ORGANISM because the renal mechanism support comes from zebrafish.

References Used in the YAML

• PMID:16722554
• PMID:18480301
• PMID:21971085
• PMID:22543976
• PMID:23389333
• PMID:25107275
• PMID:25143588
• PMID:25480730
• PMID:25838181
• PMID:27708066
• PMID:28871046
• PMID:32340490
• PMID:34586410
• PMID:35803701
• PMID:35847784
• PMID:7761412

Validation Plan

Targeted checks planned for this curation: - just validate kb/disorders/Lowe_Syndrome.yaml - just validate-references kb/disorders/Lowe_Syndrome.yaml - just validate-terms-file kb/disorders/Lowe_Syndrome.yaml

If term or reference validation fails, fix the YAML rather than weakening the evidence claims.